JP2017507917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507917A5 JP2017507917A5 JP2016546437A JP2016546437A JP2017507917A5 JP 2017507917 A5 JP2017507917 A5 JP 2017507917A5 JP 2016546437 A JP2016546437 A JP 2016546437A JP 2016546437 A JP2016546437 A JP 2016546437A JP 2017507917 A5 JP2017507917 A5 JP 2017507917A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric antigen
- antigen receptor
- medicament
- car
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 46
- 210000002865 immune cell Anatomy 0.000 claims description 27
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 230000000139 costimulatory effect Effects 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 108010087819 Fc receptors Proteins 0.000 claims description 2
- 102000009109 Fc receptors Human genes 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- -1 ICOS Proteins 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 108010065816 zeta chain antigen T cell receptor Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 description 1
- 101710128966 High affinity immunoglobulin epsilon receptor subunit alpha Proteins 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201470016 | 2014-01-14 | ||
| DKPA201470016 | 2014-01-14 | ||
| PCT/EP2015/050581 WO2015107075A1 (en) | 2014-01-14 | 2015-01-14 | Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507917A JP2017507917A (ja) | 2017-03-23 |
| JP2017507917A5 true JP2017507917A5 (enExample) | 2018-02-08 |
Family
ID=49958148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546437A Pending JP2017507917A (ja) | 2014-01-14 | 2015-01-14 | 軟骨魚類由来の抗原認識ドメインを使用したキメラ抗原受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10526406B2 (enExample) |
| EP (1) | EP3094354B1 (enExample) |
| JP (1) | JP2017507917A (enExample) |
| AU (1) | AU2015206040B2 (enExample) |
| CA (1) | CA2936693C (enExample) |
| ES (1) | ES2701846T3 (enExample) |
| WO (1) | WO2015107075A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3653212B1 (en) | 2012-12-20 | 2023-04-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| MX2017014822A (es) | 2015-05-18 | 2018-04-30 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| CN107298715B (zh) * | 2016-04-15 | 2021-05-04 | 阿思科力(苏州)生物科技有限公司 | Slit2D2-嵌合抗原受体及其应用 |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| EP3544996A2 (en) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| EP3638295A1 (en) * | 2017-06-13 | 2020-04-22 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| EP3415527B1 (de) | 2017-06-14 | 2025-12-10 | Kymab Ltd. | Verwendung der extrazellulären domäne des transferrinrezeptor 2 zur diagnostik und behandlung von primär und sekundär sklerosierenden erkrankungen |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| US12365733B2 (en) | 2017-12-29 | 2025-07-22 | Cellectis | Method for improving production of car T cells |
| AU2019209428B2 (en) | 2018-01-22 | 2025-06-26 | Endocyte, Inc. | Methods of use for CAR T cells |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| CN112236166A (zh) | 2018-06-13 | 2021-01-15 | 科马布有限公司 | 用于治疗骨疾病的转铁蛋白受体-2的拮抗剂和激动剂 |
| GB202020152D0 (en) * | 2020-12-18 | 2021-02-03 | Elasmogen Ltd | Fast-track humanisation of specific binding molecules |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| EP4141028A1 (en) * | 2021-08-31 | 2023-03-01 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main | Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars |
| CN120098132B (zh) * | 2025-01-23 | 2025-12-09 | 浙江理工大学 | 一种Cre特异性的鲨鱼单域抗体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572631B2 (en) * | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| GB201115911D0 (en) * | 2011-09-14 | 2011-10-26 | Health Prot Agency | Thermostable assay reagents |
| MX2014010183A (es) * | 2012-02-22 | 2015-03-20 | Univ Pennsylvania | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. |
| WO2013167883A1 (en) * | 2012-05-07 | 2013-11-14 | The University Court Of The University Of Aberdeen | Single domain binding molecule |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| PT3613439T (pt) * | 2013-02-15 | 2021-05-12 | Univ California | Recetor de antigénio quimérico e métodos de utilização do mesmo |
-
2015
- 2015-01-14 AU AU2015206040A patent/AU2015206040B2/en not_active Ceased
- 2015-01-14 WO PCT/EP2015/050581 patent/WO2015107075A1/en not_active Ceased
- 2015-01-14 JP JP2016546437A patent/JP2017507917A/ja active Pending
- 2015-01-14 ES ES15701312T patent/ES2701846T3/es active Active
- 2015-01-14 CA CA2936693A patent/CA2936693C/en not_active Expired - Fee Related
- 2015-01-14 EP EP15701312.9A patent/EP3094354B1/en not_active Not-in-force
- 2015-01-14 US US15/111,441 patent/US10526406B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507917A5 (enExample) | ||
| CN113286879B (zh) | 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子 | |
| JP7184866B2 (ja) | Ｐｄ１および／またはｌａｇ３結合性物質 | |
| JP7578938B2 (ja) | Ｂ７－ｈ３に対するモノクローナル抗体および細胞治療におけるその使用 | |
| CN116194130A (zh) | 新颖的抗原结合结构域和包含这些抗原结合结构域的合成抗原受体 | |
| JP2022137054A (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| TWI675845B (zh) | 能夠結合ｇｐＡ３３和ＣＤ３的雙特異性單價雙抗體及其用途 | |
| CN114072427B (zh) | 抗dll3嵌合抗原受体及其用途 | |
| Klener et al. | Immunotherapy approaches in cancer treatment | |
| CN118546960A (zh) | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 | |
| CA3169601A1 (en) | Bispecific antigen binding molecules targeting ox40 and fap | |
| CN109195994A (zh) | 针对cd137的新型双特异性多肽 | |
| AU2015357463A1 (en) | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators | |
| CA3014067A1 (en) | Modified cells for immunotherapy | |
| ES2717308T3 (es) | Células madre pluri- o multi-potentes genéticamente modificadas y sus usos | |
| JP7319250B2 (ja) | Ｓｔｒｅｐ－タグ特異的結合タンパク質およびその使用 | |
| AU2022246048A1 (en) | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging | |
| KR20230109651A (ko) | Nkg2a를 표적으로 하는 항체 및 이의 용도 | |
| JP2024519335A (ja) | がん免疫療法のための投薬レジメン | |
| CN110662760A (zh) | 人甲胎蛋白特异性t细胞受体及其用途 | |
| JP7354306B2 (ja) | 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子 | |
| CN118525029A (zh) | 假型病毒颗粒、包含其的组合物和其用途 | |
| HK40097672A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| HK40097671A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| HK40109798A (zh) | 制导和导航控制蛋白及其制备和使用方法 |